Drug Pricing
Commentary
Trump is fighting Biden’s drug-price battle — but patients will pay the cost
The Trump administration is experiencing some cognitive dissonance: The new president’s Justice Department is going to bat for former President Joe Biden and his signature legislative accomplishment. Senior Justice officials say they’ll head to court to stick up for Biden’s Inflation Reduction Act and its price controls on prescription drugs. ...
Commentary
RFK Jr. Can Breathe New Life Into HHS
Speaking to agency staffers last week, newly installed Secretary of Health and Human Services Robert F. Kennedy, Jr., insisted that “nothing is off limits” in his fight against chronic disease. It’s an encouraging message. HHS is in desperate need of modernization. Read the entire op-ed in Newsmax.
Drug Prices
New Brief: ‘Maximum Fair Price’ Policy Would Bring New Costs to Nevada Taxpayers, Put Patient Access to Health Care at Risk
SACRAMENTO – Nevada taxpayers could face millions in new bureaucratic costs and patients will likely see less access to life-saving drugs if state government mandates so-called “Maximum Fair Price” price controls on prescription drugs, finds a new brief released today by the Center for Medical Economics and Innovation at the ...
340B
Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
Commentary
Congress Eyes Regulating Drug Ads, It Won’t Mean Lower Prices
“Knowing what something costs before buying it is just common sense.” That’s how Sen. Chuck Grassley, R-Iowa, justified a bill he introduced in January to require drug companies to include a medicine’s list price in their advertisements. Unfortunately, his Drug-price Transparency for Consumers, or DTC, Act — co-sponsored by Sen. ...
Commentary
The World’s Medicine Chest
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special live ...
Commentary
Insulin prices are falling due to market forces — no price caps required
California State Sen. Scott Wiener, D-San Francisco, recently introduced legislation that would cap cost-sharing for insulin at $35 a month, regardless of whether a patient has public or private insurance. It’s a popular idea. But it may not be necessary. The cost of insulin has been falling due to market ...
Commentary
Patients Pay Dearly for Biden’s Pricing Mess
On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act. Among them is the blockbuster semaglutide, a prescription medication ...
Commentary
Creative Counting Can’t Fix The Inflation Reduction Act’s Flaws
Just three days before President Biden left office, his appointees tried to tie incoming Trump staffers’ hands on a health policy decision that affects millions of Americans and tens of billions in federal spending. On January 17, the Centers for Medicare & Medicaid Services announced a new list of 15 ...
Commentary
California could lead the way on bipartisan prescription drug reform
California State Senator Scott Wiener, D-San Francisco, recently introduced a bill aimed at reining in pharmacy benefit managers (PBMs), the middlemen largely responsible for the dysfunction plaguing our nation’s prescription drug market. Wiener’s effort should attract the support of lawmakers on both the left and right. By cracking down on ...
Trump is fighting Biden’s drug-price battle — but patients will pay the cost
The Trump administration is experiencing some cognitive dissonance: The new president’s Justice Department is going to bat for former President Joe Biden and his signature legislative accomplishment. Senior Justice officials say they’ll head to court to stick up for Biden’s Inflation Reduction Act and its price controls on prescription drugs. ...
RFK Jr. Can Breathe New Life Into HHS
Speaking to agency staffers last week, newly installed Secretary of Health and Human Services Robert F. Kennedy, Jr., insisted that “nothing is off limits” in his fight against chronic disease. It’s an encouraging message. HHS is in desperate need of modernization. Read the entire op-ed in Newsmax.
New Brief: ‘Maximum Fair Price’ Policy Would Bring New Costs to Nevada Taxpayers, Put Patient Access to Health Care at Risk
SACRAMENTO – Nevada taxpayers could face millions in new bureaucratic costs and patients will likely see less access to life-saving drugs if state government mandates so-called “Maximum Fair Price” price controls on prescription drugs, finds a new brief released today by the Center for Medical Economics and Innovation at the ...
Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
Congress Eyes Regulating Drug Ads, It Won’t Mean Lower Prices
“Knowing what something costs before buying it is just common sense.” That’s how Sen. Chuck Grassley, R-Iowa, justified a bill he introduced in January to require drug companies to include a medicine’s list price in their advertisements. Unfortunately, his Drug-price Transparency for Consumers, or DTC, Act — co-sponsored by Sen. ...
The World’s Medicine Chest
Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special live ...
Insulin prices are falling due to market forces — no price caps required
California State Sen. Scott Wiener, D-San Francisco, recently introduced legislation that would cap cost-sharing for insulin at $35 a month, regardless of whether a patient has public or private insurance. It’s a popular idea. But it may not be necessary. The cost of insulin has been falling due to market ...
Patients Pay Dearly for Biden’s Pricing Mess
On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act. Among them is the blockbuster semaglutide, a prescription medication ...
Creative Counting Can’t Fix The Inflation Reduction Act’s Flaws
Just three days before President Biden left office, his appointees tried to tie incoming Trump staffers’ hands on a health policy decision that affects millions of Americans and tens of billions in federal spending. On January 17, the Centers for Medicare & Medicaid Services announced a new list of 15 ...
California could lead the way on bipartisan prescription drug reform
California State Senator Scott Wiener, D-San Francisco, recently introduced a bill aimed at reining in pharmacy benefit managers (PBMs), the middlemen largely responsible for the dysfunction plaguing our nation’s prescription drug market. Wiener’s effort should attract the support of lawmakers on both the left and right. By cracking down on ...
